Psychedelics – reasons for caution: Stacy Fischer, Brian Anderson, Theora Cimino
GeriPal
MARCH 9, 2023
FDA is considering approval, shifting away from Schedule I restrictions, paving the way for use in clinical practice. Early data on efficacy in patients with anxiety and demoralization are promising. In our prior podcast with Ira Byock on psychedelics in 2019 we talked primarily about the potential of psychedelics.
Let's personalize your content